Second phase 3 study results for LMTX® published in the Journal of Alzheimer’s Disease

0

(IOS Press) TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of Alzheimer's Disease.

Leave A Reply

Your email address will not be published.